EA201070270A1 - Пептиды с пониженным уровнем образования димеров - Google Patents

Пептиды с пониженным уровнем образования димеров

Info

Publication number
EA201070270A1
EA201070270A1 EA201070270A EA201070270A EA201070270A1 EA 201070270 A1 EA201070270 A1 EA 201070270A1 EA 201070270 A EA201070270 A EA 201070270A EA 201070270 A EA201070270 A EA 201070270A EA 201070270 A1 EA201070270 A1 EA 201070270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dimers
peptides
formation
reduced level
level
Prior art date
Application number
EA201070270A
Other languages
English (en)
Other versions
EA018110B1 (ru
Inventor
Родерик Питер Хэфнер
Пол Лэйдлер
Original Assignee
Сиркейшиа Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134075&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715949A external-priority patent/GB0715949D0/en
Priority claimed from GB0716224A external-priority patent/GB0716224D0/en
Priority claimed from GB0723337A external-priority patent/GB0723337D0/en
Application filed by Сиркейшиа Лимитед filed Critical Сиркейшиа Лимитед
Publication of EA201070270A1 publication Critical patent/EA201070270A1/ru
Publication of EA018110B1 publication Critical patent/EA018110B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)

Abstract

Настоящее изобретение относится к пептидам, которые были сконструированы или получены в целях предупреждения образования димеров или снижения уровня их образования.
EA201070270A 2007-08-15 2008-08-15 Пептиды с пониженным уровнем образования димеров EA018110B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0715949A GB0715949D0 (en) 2007-08-15 2007-08-15 Peptide with improved solubility
GB0716224A GB0716224D0 (en) 2007-08-20 2007-08-20 Peptides for vaccine
GB0723337A GB0723337D0 (en) 2007-11-28 2007-11-28 Peptide with reduced dimer formation
PCT/GB2008/002779 WO2009022155A2 (en) 2007-08-15 2008-08-15 Peptide with reduced dimer formation

Publications (2)

Publication Number Publication Date
EA201070270A1 true EA201070270A1 (ru) 2010-08-30
EA018110B1 EA018110B1 (ru) 2013-05-30

Family

ID=40134075

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201070270A EA018110B1 (ru) 2007-08-15 2008-08-15 Пептиды с пониженным уровнем образования димеров
EA201070271A EA023303B1 (ru) 2007-08-15 2008-08-15 Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201070271A EA023303B1 (ru) 2007-08-15 2008-08-15 Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение

Country Status (24)

Country Link
US (7) US9340580B2 (ru)
EP (4) EP2190473B1 (ru)
JP (3) JP5697447B2 (ru)
KR (1) KR101699554B1 (ru)
CN (2) CN103272227B (ru)
AT (1) ATE482721T1 (ru)
AU (1) AU2008288283B2 (ru)
BR (1) BRPI0815395A2 (ru)
CA (1) CA2696563A1 (ru)
CY (2) CY1110981T1 (ru)
DE (1) DE602008002810D1 (ru)
DK (2) DK2083856T3 (ru)
EA (2) EA018110B1 (ru)
ES (1) ES2402956T3 (ru)
HK (2) HK1132194A1 (ru)
HR (2) HRP20100662T1 (ru)
IL (1) IL203943A (ru)
MX (1) MX2010001779A (ru)
NZ (2) NZ583362A (ru)
PL (1) PL2083856T3 (ru)
PT (2) PT2083856E (ru)
SI (2) SI2083856T1 (ru)
WO (4) WO2009022154A2 (ru)
ZA (2) ZA201001054B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) * 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
EP2444100A3 (en) 2008-08-15 2012-07-25 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
WO2010018384A1 (en) * 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
BRPI1008802A2 (pt) * 2009-02-05 2016-03-08 Circassia Ltd composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011085783A1 (de) * 2010-01-14 2011-07-21 Merck Patent Gmbh VARIANTEN DER GRUPPE 5-ALLERGENE DER SÜßGRÄSER MIT REDUZIERTER ALLERGENITÄT DURCH MUTAGENESE VON PROLINRESTEN
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
EP2575832B1 (en) * 2010-06-03 2017-07-26 ALK-Abelló A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
ES2561825T3 (es) * 2010-09-24 2016-03-01 María R. Díaz-Torres Péptidos
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
CA2834532A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
EP3299379A1 (en) * 2011-06-15 2018-03-28 ASIT BioTech S.A. A method for the production of hydrolyzed allergens
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
MX2015005636A (es) 2012-10-30 2015-11-16 Univ Monash Moléculas inmunoterapéuticas novedosas y sus usos.
KR20220025908A (ko) 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. 제i형 및 제iv형 과민성을 감소시키기 위한 관용유발 합성 나노담체의 국부, 병용 투여
EP3003365A1 (en) * 2013-06-05 2016-04-13 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
ES2828448T3 (es) * 2013-06-06 2021-05-26 Anergis S A Péptidos superpuestos contiguos para el tratamiento de la alergia a los ácaros del polvo doméstico
RU2689552C2 (ru) 2013-09-25 2019-05-28 Аравакс Пти Лтд Новая иммунотерапевтическая композиция и ее применения
KR20160096206A (ko) 2013-12-23 2016-08-12 알크-아벨로 에이/에스 먼지 진드기 알레르기를 치료하기 위한 펩타이드 조합 및 그의 용도
MX2016012840A (es) 2014-03-31 2017-05-09 Boehringer Ingelheim Vetmedica Gmbh Moléculas para transporte de antígeno modular mejoradas y sus usos.
EP3189147A1 (en) 2014-09-07 2017-07-12 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
CA2981422A1 (en) * 2015-03-30 2016-10-06 Osaka University Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disease containing same, and method for treating immune disease
CA2999930A1 (en) 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
BR112020001162B1 (pt) 2017-07-18 2023-11-21 Before Brands, Inc Método para fabricar uma composição alergênica misturada
US10596270B2 (en) * 2017-09-18 2020-03-24 Sutro Biopharma, Inc. Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
CN108078891B (zh) * 2017-12-28 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的保湿修复洗面奶
CN107970199B (zh) * 2018-01-03 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的牙膏
WO2020154476A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (en) 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US5126399A (en) 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US4906564A (en) 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
AU624077B2 (en) * 1987-06-17 1992-06-04 Institute For Child Health Research Cloning of mite allergens
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ES2013359A6 (es) 1988-11-04 1990-05-01 Corporacion Biolog Farmaceutic Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
DE69033949T2 (de) 1989-11-03 2002-11-14 Immulogic Pharmaceutical Corp., Cambridge Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
WO1992004445A1 (en) 1990-09-11 1992-03-19 The Western Australian Research Institute For Child Health Ltd. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
JP2632603B2 (ja) 1991-03-12 1997-07-23 アサヒビール株式会社 ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
KR100260342B1 (ko) * 1991-10-16 2000-07-01 스타세이 엘. 첸링 더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
EP0650976A4 (en) 1992-08-14 1997-10-01 Torii & Co Ltd ALLERGENIC PEPTIDE.
EP0677105B1 (en) 1992-12-31 2006-03-01 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
JPH08509966A (ja) 1993-03-12 1996-10-22 イミュロジック ファーマスーティカル コーポレイション ライグラス花粉アレルゲンのｔ細胞エピトープ
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
DE69333979T2 (de) * 1993-04-14 2006-12-21 Heska Corp.(n.d.Ges, d.Staates Delaware), Loveland T-zell epitope der hauptallergene von dermatophagoides (hausstaubmilbe)
JPH09509135A (ja) 1993-06-02 1997-09-16 ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ 免疫寛容の誘導における利用のためのクリプティックペプチド
CA2168565A1 (en) 1993-08-13 1995-03-09 Irwin J. Griffith T cell epitopes of ryegrass pollen allergen
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
WO1995028424A1 (en) * 1994-04-14 1995-10-26 Immulogic Pharmaceutical Corporation Pharmaceutical peptide formulations for treatment of dust mite allergy
US5968526A (en) * 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE19545662C2 (de) * 1995-12-07 1998-11-26 Mannesmann Sachs Ag Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung
CA2247009C (en) * 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1044019A1 (en) 1998-01-09 2000-10-18 Circassia Limited Methods and compositions for desensitisation
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
CN102764425B (zh) 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
AU2002223505B2 (en) * 2000-11-16 2006-12-07 Alk-Abello A/S Mutant allergens
US7786257B2 (en) 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
JP4812951B2 (ja) * 2001-03-21 2011-11-09 一般財団法人化学及血清療法研究所 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法
GB0108752D0 (en) 2001-04-06 2001-05-30 Isis Innovation Peptide epitopes and uses thereof
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
AUPR775401A0 (en) 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
ES2351786T3 (es) 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
ATE414534T1 (de) 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
US20040071718A1 (en) 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
WO2004078098A2 (en) 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
PT1636261E (pt) 2003-06-26 2007-11-08 Merck Patent Gmbh Proteínas trombopoietina com propriedades melhoradas
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
JP2007534633A (ja) 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
US20070225207A1 (en) 2004-04-23 2007-09-27 Novozymes A/S Group 1 Mite Polypeptide Variants
US8057800B2 (en) 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
KR101223381B1 (ko) * 2004-09-27 2013-01-16 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 이소사이클로말토올리고당 및 이소사이클로말토올리고당생성 효소와 이들의 제조 방법 및 용도
WO2006083906A2 (en) 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic phscn-peptide
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
DE602006014846D1 (de) 2005-09-15 2010-07-22 Alk Abello As Verfahren zur quantifizierung von allergenen
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
PL2059256T3 (pl) * 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2009067191A2 (en) * 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders

Also Published As

Publication number Publication date
US20160289281A1 (en) 2016-10-06
WO2009022157A3 (en) 2009-06-04
CA2696563A1 (en) 2009-02-19
PT2397154E (pt) 2015-10-29
US8551493B2 (en) 2013-10-08
WO2009022157A2 (en) 2009-02-19
JP2010536333A (ja) 2010-12-02
HRP20130270T1 (hr) 2013-04-30
EP2190473B1 (en) 2013-01-16
SI2083856T1 (sl) 2011-02-28
JP6040207B2 (ja) 2016-12-07
CN101820907A (zh) 2010-09-01
DK2190473T3 (da) 2013-03-25
EP2286833A3 (en) 2011-09-14
AU2008288283B2 (en) 2013-01-31
EA201070271A1 (ru) 2010-12-30
EP2397154B1 (en) 2015-07-15
DK2083856T3 (da) 2011-01-24
KR20100068252A (ko) 2010-06-22
CN103272227B (zh) 2014-12-10
JP2015057393A (ja) 2015-03-26
WO2009022156A3 (en) 2009-04-30
EP2286833A2 (en) 2011-02-23
KR101699554B1 (ko) 2017-01-25
AU2008288283A1 (en) 2009-02-19
PL2083856T3 (pl) 2011-04-29
HK1132194A1 (en) 2010-02-19
NZ583362A (en) 2012-06-29
SI2190473T1 (sl) 2013-05-31
EP2397154A3 (en) 2012-04-04
WO2009022155A2 (en) 2009-02-19
US20100298239A1 (en) 2010-11-25
WO2009022154A3 (en) 2009-06-04
US20130336999A1 (en) 2013-12-19
US20110123558A1 (en) 2011-05-26
US9340580B2 (en) 2016-05-17
MX2010001779A (es) 2010-07-06
EP2083856A2 (en) 2009-08-05
DE602008002810D1 (de) 2010-11-11
PT2083856E (pt) 2010-12-23
ES2402956T3 (es) 2013-05-10
EP2190473A2 (en) 2010-06-02
ATE482721T1 (de) 2010-10-15
JP5697447B2 (ja) 2015-04-08
ZA201001056B (en) 2011-04-28
JP2017061455A (ja) 2017-03-30
HK1164700A1 (en) 2012-09-28
US9744222B2 (en) 2017-08-29
BRPI0815395A2 (pt) 2015-02-10
EP2397154A2 (en) 2011-12-21
WO2009022155A3 (en) 2009-06-04
EA023303B1 (ru) 2016-05-31
US8652485B2 (en) 2014-02-18
HRP20100662T1 (hr) 2011-01-31
EA018110B1 (ru) 2013-05-30
ZA201001054B (en) 2011-04-28
NZ583361A (en) 2012-10-26
US20170157226A1 (en) 2017-06-08
WO2009022156A2 (en) 2009-02-19
CY1116828T1 (el) 2017-03-15
IL203943A (en) 2013-05-30
CY1110981T1 (el) 2015-06-11
EP2083856B1 (en) 2010-09-29
WO2009022154A2 (en) 2009-02-19
US20100260805A1 (en) 2010-10-14
CN101820907B (zh) 2013-05-01
US20140186403A1 (en) 2014-07-03
CN103272227A (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
EA201070270A1 (ru) Пептиды с пониженным уровнем образования димеров
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201490644A1 (ru) Терапевтические пептиды
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
MX2015008064A (es) Composiciones pesticidas y procesos relacionados con ellas.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
CL2009001263S1 (es) Maquina de afeitar.
CL2007002182S1 (es) Terminal.
UA106900C2 (ru) LibreOffice????!"'!DR5-!/+.)"
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
ATE532814T1 (de) Neue ammonium-polyurethan- und/oder polycarbonat- verbindungen
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
CY1121227T1 (el) Διατροφικη συνθεση, συμπληρωμα τροφης που περιλαμβανει την εν λογω διατροφικη συνθεση και kit που περιλαμβανει το εν λογω συμπληρωμα τροφης
TR201105080T2 (tr) Özet başlığı bulunamadı.
EA201201402A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
AU320051S (en) Centraliser segment
CL2008000265S1 (es) Perfil.
CL2008000272S1 (es) Perfil.
CL2008000262S1 (es) Perfil.
CL2008000267S1 (es) Perfil.
CL2008000258S1 (es) Perfil.
CL2008000275S1 (es) Perfil.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU